Journals / Türk Üroloji Dergisi/Turkish Journal of Urology / 2008 / Cilt: 34 - Sayı: 4

Value of total prostate specific antigen, complex prostate specific antigen and it is forms of volume-related in the diagnosis of prostate cancer

Prostat kanseri tanısında total prostat spesifik antijen, kompleks prostat spesifik antijen ve bunların volüm ilişkili formlarının değeri

Pages
407–412
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

PSAD, PSATzD, CPSAD and CPSATzD could be better indicators for prostate cancer than tPSA and cPSA.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: In this study, we aimed to examine value of complex prostate specific antigen (cPSA) and total prostate specific antigen (tPSA) adjusted by prostate volume measured using transrectal ultrasonography in prostate cancer detection among men with elevated tPSA.
📊
Key Findings & Data:Materials and Methods: 49 men aged 75 years or younger with serum PSA levels of 4.0-20.0 ng/mL and normal digital rectal examination findings were studied in terms of total and complex PSA (cPSA), prostate volumes with transrectal (TRUS) ultrasonography and transition zone volumes with TRUS prior to transrectal 10-core biopsy.
💡
Conclusion & Impact:PSAD, PSATzD, CPSAD and CPSATzD could be better indicators for prostate cancer than tPSA and cPSA.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Ultrason · yüksek-yoğun odaklı · transrektal

Abstract

Introduction: In this study, we aimed to examine value of complex prostate specific antigen (cPSA) and total prostate specific antigen (tPSA) adjusted by prostate volume measured using transrectal ultrasonography in prostate cancer detection among men with elevated tPSA. Materials and Methods: 49 men aged 75 years or younger with serum PSA levels of 4.0-20.0 ng/mL and normal digital rectal examination findings were studied in terms of total and complex PSA (cPSA), prostate volumes with transrectal (TRUS) ultrasonography and transition zone volumes with TRUS prior to transrectal 10-core biopsy. In addition to sole PSA values and the complex-to-total PSA ratio, volume-adjusted PSA values, PSA densities determined by TRUS (PSAD) and PSA transition zone densities (PSATzD), volume-adjusted cPSA values, cPSA densities determined by TRUS (cPSAD) and cPSA transition zone densities (cPSATzD), were compared using receiver operating characteristic (ROC) analysis. Results: Prostate cancer was diagnosed in 14 (28.5%) of the 49 men who underwent prostate biopsies. Serum c PSA levels were significantly higher in patients with prostate cancer compared with patients of benign prostate disease, but serum tPSA levels weren’t differences between prostate cancer. cPSA was not performed better than t PSA in the differentiation between benign disease and prostate cancer. Of the areas under ROC curves (AUC) of studied parameters, cPSA (AUC 0.689), PSAD (AUC 0.766), PSATzD (AUC 0.769) CPSAD (AUC 0.812) and CPSATzD (AUC 0.789) was superior to PSA (AUC 0.651) and there was no significant difference between there. Conclusions: cPSA was more specific than tPSA. PSAD, PSATzD, CPSAD and CPSATzD could be better indicators for prostate cancer than tPSA and cPSA.

Özet

Çalışmamızın amacı, yüksek tPSA düzeyli erkeklerde prostat kanserini belirlemek için cPSA ve transrektal ultrasonografi kullanarak ölçülen prostat volümü ile ilişkili tPSA ve cPSA ölçütlerini incelemektir. Bunun için serum tPSA düzeyi 4-20 ng/ml ve normal parmakla rektal inceleme bulguları olan 75 yaş ve altı 49 erkekte transrektal 10 kadran biyopsisi öncesi Trans Rektal Ultrasonografi (TRUS) ile prostat volümü ve transizyonel zon volümü ölçülüp tPSA ve cPSA çalışıldı. tPSA değerlerine ek olarak TRUS ile belirlenen PSA dansitesi değerleri (PSAD) ve Transizyonel zon PSAD (TZPSAD), Kompleks PSAD (CPSAD) ve Transizyonel zon CPSAD (TZCPSAD) değerleri ROC analizleri kullanılarak karşılaştırıldı. Prostat biyopsisi yapılan 49 erkeğin 14’ünde (%28,5) prostat kanseri tanısı kondu. Prostat kanserli gurubun tPSA değerleri (11,08±4,64 ng/ml) ve c/t PSA oranı ile BPH’li gurubun tPSA değerleri (8,92±3,68 ng/ml) ve c/tPSA oranı arasında istatistiksel olarak anlamlı bir fark bulunamadı. Bununla birlikte prostat kanserli gurubun cPSA, TPSAD, CPSAD, TZPSAD ve TZCPSAD değerleri, BPH’li gurubun değerlerinden istatistiksel olarak anlamlı derecede yüksek bulundu. tPSA, cPSA, c/tPSA, TPSAD, CPSAD, TZPSAD ve TZCPSAD ölçütlerinin ROC eğrisi altında kalan alanlar (AUC) sırası ile 0,651, 0,689, 0,537, 0,766, 0,769, 0,812 ve 0,789 bulundu. cPSA, TPSAD, CPSAD, TZPSAD ve TZCPSAD CPSAD ölçütlerinin tümör saptama özgüllüğü tPSA’den daha yüksekti. cPSA, tPSA’den daha özgüldür. TPSAD, CPSAD, TZPSAD ve TZCPSAD prostat kanseri için tPSA ve cPSA’den daha iyi göstergeler olabilir.

🔖

Cite This Article

DEVECİ, K., ÇOMAKLI, T., ÜSTĞNER, F., ŞENTÜRK, B. A., SÖĞÜT, E. (2008). Value of total prostate specific antigen, complex prostate specific antigen and it is forms of volume-related in the diagnosis of prostate cancer. Türk Üroloji Dergisi/Turkish Journal of Urology, Cilt: 34 - Sayı: 4, 407–412. https://ajindex.com/articles/328216

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Kırkali Z: Prostat kanseri etiyolojisi ve epidemiyolojisi. Prostat Kanseri GüncelYaklaşımlar Seminer Notları. Erö-zenci A (editör). İstanbul, 42-50, 1997
  2. Moyad MA: Soy, disease prevention, and prostate can-cer. Semin Urol Oncol; 17: 97-102, 1999
  3. Boyle P: Trends in cancer mortality in Europe Eur J Can-cer, 28: 7-8, 1992
  4. Kirby RS, Brawer MK, Dennis LJ: Prostate cancer test book second edition, 1-68, 1998
  5. Roberts R, Jacobsen Kalusic SK, et al: Recent declines in prostate cancer incidence and mortality J Urol; 159: 123A, 1998
  6. Özkazanç LD, Kurçenli S, Atalay S, Yekrek M: Pros-tat Kanseri Tanı Araçları Olarak PSA, Kompleks PSA ve Human Kallikrein 2. Klinik Laboratuvar 2: 11-17, 2003
  7. Djavan B, Remzi M, Zlotta R, Ravery V, Hammerer P, Reissigl A, Dobronski P, Kaisary A, Marberger M: CPSA, CPSAD of total and transitional zone, C/T PSA ratio, f/t PSA ratio, density of total and transition zone PSA: Results of the prospective multicenter European trial. Urology; 60: 4-9, 2002
  8. Croal BL, Mitchell IDC, Dikie A, et al: Complexed PSA and complexed PSA/prostate volume ratio in the di-agnosis of prostatic carcinoma. Clin Chem; 45: A108, 1999
  9. Mitchell ID, Croal BL, Dickie A, et al: A prospective study to evaluate the role of complexed prostate specific antigen ratio for the diagnosis of prostate cancer. J Urol; 165: 1549-1553, 2001
  10. Lepor H, Wang B, Sharpio E: Relationship between prostatic epithelial volume and serum PSA levels. Urolo-gy, 44: 199-205, 1994
  11. Martinez JM, Garcia MF, Villamon FR, et al: Value of prostate-specific antigen density and transitional-zone prostate-specific antigen density in the diagnosis of pros-tate cancer. Actas Urol Esp. 27: 442-9, 2003
  12. Tochigi T, Kawamura S, Numaha K, et al: Retrospec-tive evaluation of PSA density for selection of biopsy candidates with prostate spesific antigen in the gray zone. Nippon Hinyokika Gakkai Zasshi. 92: 442-9, 2001
  13. Kurita Y, Ushiyama T, Suziki K, et al: PSA value ad-justed for the transition zone volume in the diagnosis of prostate cancer. Int J Urol. 3: 367-372, 1996
  14. Anastasi G, Mongo C, Carmignani A, et al: Validity of PSA density of the transition zone in the diagnosis of prostate cancer. Arch Ital Urol Androl. 72: 190-3, 2000
  15. Winkler MH, Kullinskaya E, Gillatt DA: Prediction of prostate cancer in extended-field biopsies of the prostate. BJU International. 93: 516, 2004
  16. Hiroshi M, Yoichi A, Yoshitaka A, et al: Complexed prostate specific antige